Commentary on Greenberg et al., "Prescribing anti-amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions" [. 2023; 9(4):e12426. doi.org/10.1002/trc2.12426].
作者信息
Hill Carl V, Pike Joanne
机构信息
Alzheimer's Association Chicago Illinois USA.
出版信息
Alzheimers Dement (N Y). 2024 Jan 26;10(1):e12443. doi: 10.1002/trc2.12443. eCollection 2024 Jan-Mar.
Abstract
摘要
相似文献
1
Commentary on Greenberg et al., "Prescribing anti-amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions" [. 2023; 9(4):e12426. doi.org/10.1002/trc2.12426].对格林伯格等人所著《开具抗淀粉样蛋白免疫疗法治疗阿尔茨海默病：充分告知患者决策》的评论[. 2023; 9(4):e12426. doi.org/10.1002/trc2.12426]
Alzheimers Dement (N Y). 2024 Jan 26;10(1):e12443. doi: 10.1002/trc2.12443. eCollection 2024 Jan-Mar.
2
Open peer commentary on "Prescribing anti-amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions".关于“开具抗淀粉样蛋白免疫疗法治疗阿尔茨海默病：充分告知患者决策”的公开同行评论
Alzheimers Dement (N Y). 2023 Nov 20;9(4):e12437. doi: 10.1002/trc2.12437. eCollection 2023 Oct-Dec.
3
Prescribing anti-amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions.开抗淀粉样蛋白免疫疗法治疗阿尔茨海默病：充分告知患者以助其做出决策。
Alzheimers Dement (N Y). 2023 Oct 4;9(4):e12426. doi: 10.1002/trc2.12426. eCollection 2023 Oct-Dec.
4
The Teflon hypothesis.聚四氟乙烯假说。
Brain Commun. 2023 Jul 13;5(4):fcad203. doi: 10.1093/braincomms/fcad203. eCollection 2023.
5
In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer's disease.血液中：阿尔茨海默病淀粉样蛋白病理学和神经退行性变的生物标志物。
Brain Commun. 2020 Jul 2;2(1):fcaa054. doi: 10.1093/braincomms/fcaa054. eCollection 2020.
6
Candesartan-the next anti-amyloid drug?坎地沙坦——下一种抗淀粉样蛋白药物？
Brain Commun. 2022 Nov 7;4(6):fcac293. doi: 10.1093/braincomms/fcac293. eCollection 2022.
7
Modelling Alzheimer's disease in a dish: dissecting amyloid-β metabolism in human neurons.在培养皿中模拟阿尔茨海默病：剖析人类神经元中的淀粉样β蛋白代谢
Neuronal Signal. 2024 Jan 11;8(1):NS20230020. doi: 10.1042/NS20230020. eCollection 2024 Jan.
8
Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer's disease and related dementias?5型磷酸二酯酶抑制剂能否成为治疗阿尔茨海默病及相关痴呆症的潜在疗法？
Brain Commun. 2022 Oct 11;4(5):fcac260. doi: 10.1093/braincomms/fcac260. eCollection 2022.
9
Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.血浆神经元外泌体可作为 HIV 感染和阿尔茨海默病认知障碍的生物标志物。
J Neurovirol. 2019 Oct;25(5):702-709. doi: 10.1007/s13365-018-0695-4. Epub 2019 Jan 4.
10
Eigenvector centrality and its variability over time are promising indicators of alterations in brain function due to early amyloid deposition.特征向量中心性及其随时间的变化是早期淀粉样蛋白沉积导致脑功能改变的有前景的指标。
Brain Commun. 2023 Apr 6;5(3):fcad104. doi: 10.1093/braincomms/fcad104. eCollection 2023.
本文引用的文献
1
Prescribing anti-amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions.开抗淀粉样蛋白免疫疗法治疗阿尔茨海默病：充分告知患者以助其做出决策。
Alzheimers Dement (N Y). 2023 Oct 4;9(4):e12426. doi: 10.1002/trc2.12426. eCollection 2023 Oct-Dec.
2
2023 Alzheimer's disease facts and figures.2023 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14.
3
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria.阿尔茨海默病药物试验中的多样性：入选标准的重要性。
Alzheimers Dement. 2022 Apr;18(4):810-823. doi: 10.1002/alz.12433. Epub 2021 Sep 30.
4
Inequalities in dementia incidence between six racial and ethnic groups over 14 years.14年间六个种族和民族群体在痴呆症发病率上的不平等。
Alzheimers Dement. 2016 Mar;12(3):216-24. doi: 10.1016/j.jalz.2015.12.007. Epub 2016 Feb 11.
Zotero 插件